Cystic fibrosis has undergone one of the most dramatic therapeutic transformations in modern medicine. Median predicted survival stood at 36 years in 2006. With elexacaftor/tezacaftor/ivacaftor, the highly effective CFTR modulator now standard for patients with at least one responsive variant, microsimulation modeling projects median survival approaching 82 years when treatment begins in adolescence. Adults now constitute the majority of the CF population, and those aged 40 and older are the fastest-growing cohort. CF is no longer a pediatric disease. It is increasingly a condition primary care manages across decades.
AAVBC's Cystic Fibrosis Quick Reference Guide provides primary care clinicians with a practical reference for CF as a lifelong adult condition. It covers recognition, ICD-10 coding, comorbidity documentation, CFTR modulator therapy, and MEAT standards — grounded in current Cystic Fibrosis Foundation guideline evidence.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of cystic fibrosis — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Cystic fibrosis has undergone one of the most dramatic therapeutic transformations in modern medicine. Median predicted survival stood at 36 years in 2006. With elexacaftor/tezacaftor/ivacaftor, the highly effective CFTR modulator now standard for patients with at least one responsive variant, microsimulation modeling projects median survival approaching 82 years when treatment begins in adolescence. Adults now constitute the majority of the CF population, and those aged 40 and older are the fastest-growing cohort. CF is no longer a pediatric disease. It is increasingly a condition primary care manages across decades.
AAVBC's Cystic Fibrosis Quick Reference Guide provides primary care clinicians with a practical reference for CF as a lifelong adult condition. It covers recognition, ICD-10 coding, comorbidity documentation, CFTR modulator therapy, and MEAT standards — grounded in current Cystic Fibrosis Foundation guideline evidence.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of cystic fibrosis — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
